Multiple sclerosis: Lessons from molecular neuropathology

Experimental Neurology

Volumn 262, Issue Part A, 2014, Pages 2-7

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Demyelination; Multiple sclerosis; Neurodegeneration

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

AGE; B LYMPHOCYTE; BRAIN CORTEX; BRAIN CORTEX LESION; BRAIN DAMAGE; CELL ACTIVATION; CEREBROSPINAL FLUID; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MENINGITIS; MICROGLIA; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; RESPIRATORY BURST; REVIEW; SUBPIAL CORTICAL LESION; WHITE MATTER; CENTRAL NERVOUS SYSTEM; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY;

CENTRAL NERVOUS SYSTEM; HUMANS; MULTIPLE SCLEROSIS;

EID: 84908616972     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.12.003     Document Type: Review

References (98)

1. Aboul-Enein F., Rauschka H., Kornek B., Stadelmann C., Stefferl A., Brück W., Lucchinetti C.F., Schmidbauer M., Jellinger K., Lassmann H. Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropathol. Exp. Neurol. 2003, 62:25-33.
2. Appel S.H., Bornstein M.B. The application of tissue culture to the study of experimental allergic encephalomyelitis. II. Serum factors responsible for demyelination. J. Exp. Med. 1964, 119:303-312.
3. Babinski J. Recherches sur l'anatomie pathologique de la sclerose en plaque et etude comparative des diverses varietes de la scleroses de la moelle. Arch Physiol. (Paris) 1885, 5-6:186-207.
4. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
5. Benjamins J.A. Direct effects of secretary products of immune cells on neurons and glia. J. Neurol. Sci. 2013, 333:30-36.
6. Bo L., Vedele r C.A., Nyland H.I., Trapp B.D., Mork S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723-732.
7. Bornstein M.B., Appel S.G. The application of tissue culture to the study of experimental allergic encephalomyelitis. I. Pattern of demyelination. J. Neuropathol. Exp. Neurol. 1961, 20:141-147.
8. Bornstein M.B., Appel S.H. Tissue culture studies of demyelination. Ann. N. Y. Acad. Sci. 1965, 122:280-286.
9. Brink B.P., Veerhuis R., Breij E.C., van der Valk P., Dijkstra C.D., Bo L. The pathology of multiple sclerosis is location dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 2005, 64:147-155.
10. Brosnan C.F., Raine C.S. The astrocyte in multiple sclerosis revisited. Glia 2013, 61:453-465.
11. Brownell B., Hughes J.T. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1962, 25:315-320.
12. Cannella B., Gaupp S., Omari K.M., Raine C.S. Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions. J. Neuroimmunol. 2007, 188:128-137.
13. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C.A., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
14. Choi S., Howell O.W., Carassiti D., Magliozzi R., Gveric D., Muraro P.A., Nicholas R., Roncaroli F., Reynolds R. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135:2925-2937.
15. Cifelli A., Arridge M., Jezzard P., Esiri M.M., Palace J., Matthews P.M. Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 2002, 52:650-653.
16. Connor J.R., Menzies S.L. Cellular management of iron in the brain. J. Neurol. Sci. 1995, 134:33-44. (Suppl.).
17. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011, 18:21-29.
18. Dowling P.C., Kim S.U., Murray M.R., Cook S.D. Serum 19S and 7S demyelinating antibodies in multiple sclerosis. J. Immunol. 1968, 101:1101-1104.
19. Dubois-Dalq M., Niedieck B., Buyse M. Action of anticerebroside sera on myelinated nervous tissue cultures. Pathologica 1970, 5:331-347.
20. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59:478-489.
21. Eisele S., Krumbholz M., Fischer M.T., Mohan H., Junker A., Arzberger T., Hohlfeld R., Bradl M., Lassmann H., Meinl E. Prospects of transcript profiling for mRNAs and microRNAs using formalin fixed paraffin embedded dissected autoptic multiple sclerosis lesions. Brain Pathol. 2012, 22:607-612.
22. Elliott C., Lindner M., Arthur A., Brennan K., Jarius S., Hussey J., Chan A., Stroet A., Olsson T., Willison H., Barnett S., Meinl E., Linington C. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012, 135:1819-1833.
23. Felts P.A., Woolston A.M., Fernando H.B., Asquith S., Gregson N.A., Mizzi O.J., Smith K.J. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 2005, 128:1649-1666.
24. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
25. Fischer M.T., Sharma R., Lim J., Haider L., Frischer J., Drexhage J., Mahad D., Bradl M., van Horssen J., Lassmann H. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135:886-899.
26. Fischer M.T., Wimmer I., Höftberger R., Gerlach S., Haider L., Zrzavy T., Hametner S., Mahad D., Binder C.J., Krumbholz M., Bauer J., Bradl M., Lassmann H. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013, 136:1799-1815.
27. Frischer J.M., Bramow S., Dal Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
28. Gilmore C.P., Donaldson I., Bo L., Owens T., Lowe J., Evangelou N. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry 2009, 80:182-187.
29. Grundke Iqbal I., Bornstein M.B. Multiple sclerosis: serum gamma globulin and demyelination in culture. Neurology 1980, 30:749-754.
30. Grundke Iqbal I., Raine C.S., Johnson A.B., Brosnan C.F., Bornstein M.B. Experimental allergic encephalomyelitis. Characterization of serum factors causing demyelination and swelling of myelin. J. Neurol. Sci. 1981, 50:63-79.
31. Haider L., Fischer M.T., Frischer J.M., Bauer J., Höftberger R., Botond G., Esterbauer H., Binder C.J., Witztum J.L., Lassmann H. Oxidative damage and neurodegeneration in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
32. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
33. Hametner S., Wimmer I., Haider L., Pfeiffenbring S., Brück W., Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 2013, (e.pub ahead of print).
34. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., Femald G.H., Gerlitz B., Robinson W.H., Baranzini S.E., Grinnell B.W., Raine C.S., Sobel R.A., Han D.K., Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
35. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H., HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
36. Henderson A.P.D., Barnett M.H., Parratt J.D.E., Prineas J.W. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 2009, 66:739-753.
37. Hochmeister S., Grundtner R., Bauer J., Engelhardt B., Lyck R., Gordon G., Korosec T., Kutzelnigg A., Berger J.J., Bradl M., Bittner R.E., Lassmann H. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2006, 65:855-865.
38. Howell O.W., Reeves C.A., Nicholas R., Carassiti D., Radotra B., Gentleman S.M., Serafini B., Aloisi F., Roncaroli F., Magliozzi R., Reynolds R. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
39. Hughes D., Field E.J. Myelinotoxicity of serum and spinal fluid in multiple sclerosis: a critical assessment. Clin. Exp. Immunol. 1967, 2:295-309.
40. Huitinga I., Erkut Z.A., van Beurden D., Swab D.F. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann. Neurol. 2004, 55:37-45.
41. Kanter J.L., Naravana S., Ho P.P., Catz I., Warren K.G., Sobel R.A., Steinman L., Robinson W.H. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 2006, 12:138-143.
42. Kidd T., Barkhof F., McConnell R., Algra P.R., Allen I.V., Revesz T. Cortical lesions in multiple sclerosis. Brain 1999, 122:17-26.
43. Kolasinski J., Stagg C.J., Chance S.A., DeLuca G.C., Esiri M.M., Chang E.H., Palace J.A., McNab J.A., Jenkinson M., Miller K.L., Johansen-Berg H. A combined post-mortem MRI and quantitative histological study of multiple sclerosis pathology. Brain 2012, 135:2938-2951.
44. Kornek B., Storch M., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am. J. Pathol. 2000, 157:267-276.
45. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Brück W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
46. Lassmann H. The architectures of active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2011, 37:698-710.
47. Lassmann H., Kitz K., Wisniewski H.M. In vivo effect of sera from animals with chronic experimental allergic encephalomyelitis on central and peripheral myelin. Acta Neuropathol. 1981, 55:297-306.
48. Lassmann H., Stemberger H., Kitz K., Wisniewski H.M. In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis: antibody nature of the demyelinating factor and the role of complement. J. Neurol. Sci. 1983, 59:123-137.
49. Lassmann H., Brück W., Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
50. Lassmann H., van Horssen J., Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8:647-656.
51. Leray E., Yaouang J., LePage E., Coustans M., Laplaud D., Oger J., Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133:1900-1913.
52. Lily O., Palace J., Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004, 127:269-279.
53. Linington C., Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with the antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 1987, 17:61-69.
54. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 1988, 130:443-454.
55. Lisak R.P., Nedelkoska L., Studzinski D., Bealmear B., Xu W., Benjamins J.A. Cytokines regulate neuronal gene expression: differential effects of Th1, Th2 and monocytes/macrophage cytokines. J. Neuroimmunol. 2011, 238:19-33.
56. Lisak R.P., Benjamins J.A., Nedelkoska L., Barger J.L., Ragheb S., Fan B., Ouamara N., Johnson T.A., Rajasekharan S., Bar-Or A. Secretory products of multiple sclerosis B-cells are cytotoxic to oligodendrocytes in vitro. J. Neuroimmunol. 2012, 246:85-95.
57. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A.M., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
58. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
59. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
60. Lucchinetti C.F., Popescu B.F.G., Bunyan R.F., Moll N.M., Roemer S.F., Lassmann H., Brück W., Parisi J.E., Scheithauer B.W., Giannini C., Weigand S.D., Mandrekar J., Ransohoff R.M. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365:2188-2197.
61. Lumsden C.E. The neuropathology of multiple sclerosis. Handbook of clinical neurology 1970, vol. 9:217-309. Elsevier, New York. P.I. Vinken, G.W. Bruyn (Eds.).
62. Lumsden C.E. The immunogenesis of the multiple sclerosis plaque. Brain Res. 1971, 28:365-390.
63. Mahad D., Ziabreva I., Lassmann H., Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008, 131:1722-1735.
64. Marburg O. Die sogenannte "akute multiple Sklerose". Jahrb. Psychol. 1906, 27:1-99.
65. Marik C., Felts P., Bauer J., Lassmann H., Smith K.J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain 2007, 130:2800-2815.
66. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., Al-Hayani A., Davies S.N., Rasband M.N., Olsson T., Moldenhauer A., Velhin S., Hohlfeld R., Meinl E., Linington C. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007, 204:2363-2372.
67. Matsushita T., Masaki K., Suzuki S., Matsuoka T., Yonekawa T., Wu X.M., Tabira T., Iwaki T., Kira J. Astrocytopathy in neuromyelitis optica, multiple sclerosis and Balo's disease. Rinsho Shinkeigaku 2011, 51:898-900.
68. Moll N.M., Rietsch A.M., Ransohoff A.J., Cossoy M.B., Huang D., Eichler F.S., Trapp B.D., Ransohoff R.H. Cortical demyelination in PML and MS: similarities and differences. Neurology 2008, 70:336-343.
69. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
70. Mycko M.P., Papoian R., Boschert U., Raine C.S., Selmaj K.W. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003, 126:1048-1057.
71. Na S.Y., Cao Y., Toben C., Nitschke L., Stadelmann C., Gold R., Schimpl A., Hünig T. Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008, 131:2353-2365.
72. Nitsch R., Pohl E.E., Smorodchenko A., Infante-Duarte C., Atkas O., Zipp F. Direct impact on T-cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 2004, 24:2458-2464.
73. O'Connor K.C., McLaughlin K.A., De Jager P.L., Chitnis T., Bettelli E., Xu C., Robinson W.H., Cherry S.V., Bar-Or A., Banwell B., Fukaura H., Fukazawa T., Tenembaum S., Wong S.J., Tavakoli N.P., Idrissova Z., Rostami K., Pohl D., Dale R.C., Freedman M., Steinman L., Buckle G.J., Kuchroo V.K., Hafler D.A., Wucherpfennig K.W. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 2007, 13:211-217.
74. Parratt J.D., Prineas J.W. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult. Scler. 2010, 16:1156-1172.
75. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., Wucherpfennig K., Turley S., Carroll M.C., Sobel R.A., Bettelli E., Kuchroo V.K. Th17 cells induce ectopic lymphoid follicles in central nervous tissue inflammation. Immunity 2011, 35:986-996.
76. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transsected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50:389-400.
77. Prineas J.W., Kwon E.E., Cho E.S., Sharer L.R., Barnett M.H., Oleszak E.L., Hoffman B., Morgan B.P. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 2001, 50:646-657.
78. Probert L., Eugster H.P., Akassoglou K., Bauer J., Frei K., Lassmann H., Fontana A. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000, 123:2005-2019.
79. Ramanathan M., Weinstock-Guttman B., Nguyen L.T., Badgett D., Miller C., Patrick K., Brownscheidle C., Jacobs L. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 2001, 116:213-219.
80. Rostasy K., Mader S., Schanda K., Huppke P., Gärtner J., Kraus V., Karenfort M., Tibussek D., Blaschek A., Bajer-Kornek B., Leitz S., Schimmel M., Di Pauli F., Berger T., Reindl M. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch. Neurol. 2012, 69:752-756.
81. Saxena A., Bauer J., Scheikl T., Zappulla J., Audebert M., Desbois S., Waisman A., Lassmann H., Liblau R.S., Mars L.T. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J. Immunol. 2008, 181:1617-1621.
82. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
83. Sharma R., Fischer M.T., Bauer J., Felts P.A., Smith K.J., Misu T., Fujihara K., Bradl M., Lassmann H. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol. 2010, 120:223-236.
84. Shindler K.S., Ventura E., Rex T.S., Elliott P., Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 2007, 48:3602-3609.
85. Smith K.J., Kapoor P.A., Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999, 9:69-92.
86. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallström E., Kerschensteiner M., Olsson T., Linington C., Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998, 8:681-694.
87. Storch M.K., Bauer J., Linington C., Olsson T., Weissert R., Lassmann H. Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J. Neuropathol. Exp. Neurol. 2006, 65:1137-1142.
88. Stys P.K. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 2005, 133:3-13.
89. Su K., Bourdette D., Forte M. Genetic inactivation of mitochondria-targeted redox enzyle p66ShcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges. Front. Physiol. 2012, 3:285.
90. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8:280-291.
91. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
92. Van der Star B.J., Vogel D.Y., Kipp M., Puentes F., Baker D., Amor S. In vitro and in vivo models of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2012, 11:570-588.
93. Vercellino M., Masera S., Lorenzatti M., Condello C., Merola A., Mattioda A., Tribolo A., Capello E., Mancardi G.L., Mutani R., Giordana M.T., Cavalla P. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep grey matter. J. Neuropathol. Exp. Neurol. 2009, 68:489-502.
94. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract. Neurol. 2008, 4:159-169.
95. Werner P., Pitt P., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 2001, 50:169-180.
96. Whitney L.W., Becker K.G., Tresser N.J., Caballero-Ramos C.I., Munson P.J., Prabhu V.V., Trent J.M., McFarland H.F., Biddison W.E. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 1999, 46:425-428.
97. Wiendl H., Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009, 72:1008-1015.
98. Zeis T., Propst A., Steck A.J., Stadelmann C., Brück W., Schaeren-Wiemers N. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol. 2009, 19:459-466.